	Cancer Antigen-125 and Carcinoembryonic Antigen in Determining Malignancy Risk in Epithelial Ovarian Tumor: An Observational Study. JNMA J Nepal Med Assoc Singh R, Shakya B. PMID: 41783428 [PubMed - in process]
	Identification of Genetic Variants Among Breast Cancer Patients and At-Risk Individuals: A Cohort Study in Sri Lanka. Breast Cancer (Auckl) Yatawara L, Hewavithana B, Ramanayake AP, Wickramasinghe S, Amarasiri M. PMID: 41783385 [PubMed]
	The Information Needs of Breast Cancer Patients at All Stages of Their Journey: A Scoping Review. Patient Prefer Adherence Priambodo AP, Trisyani Y, Nuraeni A, Anna A, Sugiharto F. PMID: 41783122 [PubMed]
	Chronic Mycobacterium kansasii Pleural Infection Mimicking Metastatic Breast Cancer: A Seven-Year Diagnostic Odyssey and the Critical Role of Metagenomic Sequencing. Infect Drug Resist Fang T, Hu P, Zhang Y, Hu B, Miao Q. PMID: 41782849 [PubMed]
	Pre-operative Axillary Staging in Breast Cancer: Implications and Outcome. Cureus Irshad H, Mavor F, Avesi S, Bourdon-Pierre R, Win M, Mohammad Isa Z. PMID: 41782783 [PubMed]
	Comparative Outcomes of Doxorubicin and Cyclophosphamide with Sequential versus Concurrent Paclitaxel in the Adjuvant Treatment of Non-Metastatic Breast Cancer: A Cross-Sectional Analytical Study. JNMA J Nepal Med Assoc Paudel B, Paudel B, Shrestha R, Panthi B, Shilpakar R, Dulal S, Kharel S, Dhungana R, Shrestha B, Singh YP. PMID: 41782722 [PubMed - in process]
	Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study. Breast Cancer Res Zou L, Tang X, Deng P, Liu Y, Yang T, Tan X, Yang L, Li W, Zeng X. PMID: 41782020 [PubMed - as supplied by publisher]
	Omitting axillary lymph node dissection or not? A multicenter, retrospective study for breast cancer patients potentially eligible for abemaciclib since the SENOMAC trial. World J Surg Oncol Xu Z, Zeng Y, Shen K, Hu C, Gao W. PMID: 41782017 [PubMed - as supplied by publisher]
	Impact of germline genetic variation on breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer Gutiérrez-González A, Maciel-Cruz EJ, Reynoso-Noverón N, Mohar-Betancourt A, Villarreal-Garza C, Grimaldo L, Trujillo-Martínez M, Gómez-Flores-Ramos L. PMID: 41781907 [PubMed - as supplied by publisher]
	Sonodynamic Therapy-Enhanced Immunotherapy for Triple-Negative Breast Cancer: Mechanistic Advances, Nanoplatform Strategies, and Clinical Prospects. Mol Imaging Biol Tatiparthi R, Panda A, Chaitanya M, Gashe F, Hasan G, Yarlagadda R. PMID: 41781803 [PubMed - as supplied by publisher]
	Finding the optimal recall rate in breast cancer screening: results from the ROCS study. Eur Radiol van der Waal D, Abbey CK, Tetteroo E, Geertse TD, Smid-Geirnaerdt MJA, Sechopoulos I, Broeders MJM. PMID: 41781728 [PubMed - as supplied by publisher]
	Magnification-independent breast cancer diagnosis using a GWO-enhanced vision transformer with multi-stage stain normalization. Sci Rep Fatma T, Sahu PK, Choudhury S, Wunnava A. PMID: 41781597 [PubMed - as supplied by publisher]
	AI-based BRAIx risk score for the intermediate-term prediction of breast cancer: a population cohort study. Lancet Digit Health Frazer HML, Hopper JL, Nguyen TL, Elliott MS, Kunicki KM, Al-Qershi O, Schmidt DF, Makalic E, Li S, Fox SK, Dowty JG, Peña-Solorzano CA, Kwok CF, Chen Y, Wang C, Lippey J, Brotchie P, Carneiro G, Strand F, McCarthy DJ. PMID: 41781282 [PubMed - as supplied by publisher]
	Amide Proton Transfer-Weighted Imaging Combined with Fat Fraction Imaging for Diagnosis of Triple-Negative Breast Cancer. Acad Radiol Yin X, Wang S, Guo Z, Zhang M, Lin L, Zhang L. PMID: 41781261 [PubMed - as supplied by publisher]
	Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease. Ann Oncol Curigliano G, Hu X, Dent R, Yonemori K, Barrios CH, Pierga JY, Puglisi F, Ferrero JM, Jung KH, Bagegni NA, Collignon J, Gil-Gil M, Wu X, Andrzejuk-, Schwaederle M, Anand S, Bardia A. PMID: 41780642 [PubMed - as supplied by publisher]
	Aloperine exerts anti-ovarian cancer effects by regulating the tricarboxylic acid cycle and glycolysis: A comprehensive study integrating network pharmacology, molecular docking, metabolomics, and experimental validation. J Ethnopharmacol Zhang D, Yang Q, Xia H, Jiang Q, Sun J, Bai R. PMID: 41780620 [PubMed - as supplied by publisher]
	Thermal signatures in breast cancer: Deciphering latent biomarkers through deep learning and explainable AI. J Therm Biol Kansal S, Kaur S, Jain A, Bansal S, Gambhir M. PMID: 41780328 [PubMed - as supplied by publisher]
	MRI in advanced ovarian cancer: multicentre MISSION trial. Eur J Cancer Berardi E, J van Driel W, H M Hermans R, N Gaarenstroom K, A R Lok C, Persijn-van Meerten ELV, Nederend J, Lambrechts S, Lopez-Yurda M, P Engbersen M, J V Rijsemus C, M J Lambregts D, Laghi A, G J Aalbers A, G H Beets-Tan R, F M Kok N, J Lahaye M. PMID: 41780181 [PubMed - as supplied by publisher]
	Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study). J Clin Oncol Li T, Zhou T, Wang B, Tao Z, Zhao M, Wang L, Jin J, Zhao Y, Gong C, Cao J, Miao H, Peng W, Wang J, Jin M, Hu X, Zhang J. PMID: 41779972 [PubMed - as supplied by publisher]
	Integrated strategy for breast cancer biomarker analysis using dual ionic liquid aqueous biphasic systems and microfluidic immunoassays. Lab Chip Mendes MSM, Agostinho I, Souza MC, Chu V, Freire MG, E Silva FA, Conde JP. PMID: 41779543 [PubMed - as supplied by publisher]

Articles 1 - 20 / 325121

Page 1 of 16257



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy